Kezar Life Sciences Inc., a clinical-stage biotechnology company, has reported its financial results for the first quarter ended March 31, 2025. The company reported a net loss of $16.6 million, or $2.27 per basic and diluted common share, compared to a net loss of $21.7 million, or $2.98 per basic and diluted common share, in the first quarter of 2024. General and administrative expenses decreased by $1.1 million to $5.4 million, primarily due to reduced legal and professional service expenses and non-cash stock-based compensation. Research and development expenses also decreased by $5.0 million to $12.2 million, primarily as a result of the strategic decision to terminate the PALIZADE trial in October 2024, along with decreased manufacturing and facility-related expenses. As of March 31, 2025, the company held cash, cash equivalents, and marketable securities totaling $114.4 million, a decrease from $132.2 million as of December 31, 2024, primarily due to cash used in operations. In a significant business update, Kezar Life Sciences announced positive topline data from the PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis $(AIH)$. The study reported promising safety and efficacy results, including durable and steroid-sparing remissions, in a difficult-to-treat patient population. The company is actively engaging with the FDA's Division of Hepatology and Nutrition to align on an appropriate trial design to further demonstrate the clinical benefit of zetomipzomib in AIH.